At FDA, Changes In Name Only–Agency Puts Business interests Above Safety Fri, 30 Sep 2005 The sudden resignation of FDA Commissioner, Lester Crawford, after just two months in office, has prompted a bipartisan Senate investigation and requests both by the Senate committee . . . Continue reading →
Lester Crawford
How Did the Vioxx Debacle Happen? USA Today / Lancet
How Did the Vioxx Debacle Happen? USA Today / Lancet Tue, 12 Oct 2004 Dr. Eric Topol of the Cleveland Clinic: “The senior executives at Merck and the leadership at the FDA share responsibility for not having taken appropriate action and not . . . Continue reading →
FDA Commissioner Nominee told Senate He’s Open to Independent Safety Unit / Avonex Warning
FDA Commissioner Nominee told Senate He’s Open to Independent Safety Unit / Biogen issues Avonex Warning Fri, 18 Mar 2005 It would be impossible to gain insight into Lester Crawford’s confirmation hearings by the Senate Health, Education, Labor and Pensions committee if . . . Continue reading →
Infomail Archive
Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck . . . Continue reading →
Pfizer CEO earned $16 milion – 72% Increase / V-P Tells Congress How to Save $37.8 billion in cost of drugs
Pfizer CEO earned $16 milion-72% Increase / V-P Tells Congress How to Save $37.8 billion in cost of drugs Thu, 10 Mar 2005 In his February 16 testimony before the Senate Committee on Health, Education, Labor and Pensions, Dr. Peter Rost, Pfizer . . . Continue reading →
Corporate Culture of Denial Results in Preventable Deaths
Corporate Culture of Denial Results in Preventable Deaths Fri, 7 Jan 2005 Failure to disclose the hazardous effects of Vioxx and Prozac are evidence of a corporate culture that has run amok. Uncovered company documents – some obtained through litigation, others unearthed . . . Continue reading →
FDA Commissioner Lester Crawford Resigns – AP
FDA Commissioner Lester Crawford Resigns – AP Fri, 23 Sep 2005 The Associated Press reports that the embattled FDA commissioner, Lester Crawford, a veterenarian, who headed the agency since Marc McLellan moved over to the Center for Medicare & Medicaid Services, has . . . Continue reading →
Safety of American Drugs Questioned – Assoc Press
Safety of American Drugs Questioned – Assoc Press Thu, 2 Dec 2004 In his CNN news program last evening, Lou Dobbs said the question is no longer whether something is wrong with the FDA’s performance in protecting the public from unsafe drugs–but . . . Continue reading →
FDA Critics Slam Plan for Safety Reform – Nature
FDA Critics Slam Plan for Safety Reform – Nature Thu, 17 Feb 2005 This is smoke and mirrors and musical chairs. Vera Sharav Alliance for Human Research Protection, New York http://www.nature.com/news/2005/050214/full/050214-11.html Published online: 17 February 2005; | doi:10.1038/news050214-11 FDA critics slam plan . . . Continue reading →
FDA Is Flexing Less Muscle where Safety is the Issue – Wash Post
FDA Is Flexing Less Muscle where Safety is the Issue – Wash Post Thu, 18 Nov 2004 The Washington Post examines FDA’s record of surveillance and the evidence is clear: since 1992 when Congress required drug companies to pay users fees to . . . Continue reading →
Cover Letter – Comments to FDA Re Anthrax Vaccine
Cover Letter – AHRP Ethical and Scientific Objections to FDA’s Proposed Licensure of Anthrax Vaccine related links: Comments Submitted to FDA re Anthrax Vaccine (312K pdf) Who Is Protecting The Public Health? By Meryl Nass, Z Magazine March 29, 2005 Lester Crawford, . . . Continue reading →
Daniel Troy Legacy: Public Virtually Defenseless against Unsafe Drugs
Daniel Troy Legacy: Public Virtually Defenseless against Unsafe Drugs Thu, 18 Nov 2004 The Associated Press reports that at a Congressional hearing today, Dr. David Graham a drug safety expert at the FDA told the Senate Finance Committee that the public is . . . Continue reading →